Thermo Fisher Scientific to Acquire QIAGEN
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN.
QIAGEN
The transaction values QIAGEN at approximately $11.5 billion at current exchange rates, which includes the assumption of approximately $1.4 billion of net debt.
“We are excited to bring together our complementary offerings to advance our customers’ important work, from discovery to diagnostics,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs. For shareholders, we expect the transaction to be immediately accretive and to generate significant cost and revenue synergies.”
QIAGEN is a leading provider of life science and molecular diagnostic solutions and employs approximately 5,100 people at 35 locations in more than 25 countries. The company generated 2019 revenue of $1.53 billion. Its sample preparation technologies are used to extract, isolate and purify DNA, RNA and proteins from a wide range of biological samples. The company’s assay technologies are then used to amplify and enrich these biomolecules to make them readily accessible for analysis. In addition, QIAGEN’s instruments can be used to automate these workflows, while its bioinformatics systems provide customers with relevant, actionable insights.
“Our vision at QIAGEN has always been to make improvements in life possible with our differentiated Sample to Insight molecular testing solutions,” said Thierry Bernard, interim chief executive officer of QIAGEN N.V. and senior vice president, head of the molecular diagnostics business area. “This strategic step with Thermo Fisher will enable us to enter a promising new era and will give our employees the opportunity to have an even greater impact. The combination is designed to deliver significant cash value to our shareholders, while enabling us to accelerate the expansion of our solutions to provide customers worldwide with breakthroughs that advance our knowledge about the science of life and improve health outcomes.”
Casper concluded, “We look forward to welcoming QIAGEN’s employees to Thermo Fisher and are excited about the new opportunities we’ll have to advance precision medicine through new molecular diagnostics and improved life sciences workflows.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
BOSELLO now fully part of the ZEISS Group - BOSELLO HIGH TECHNOLOGY becomes Carl Zeiss X-ray Technologies Srl
Destination China as Level Sensors and Transmitters Markets Make a Comeback - Increased investments in manufacturing and greater automated production to fuel demand in emerging economies
New study supports use of PCA3-based test for prostate cancer diagnosis - European commercialization in progress
European multi-center study suggests PCA3 test more accurate for prostate cancer
Vibrations key to efficiency of green fluorescent protein - Charting femtosecond energy flow could aid redesign of molecules to improve light capture
Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity
Chiral Technologies Europe Acquires ChromTech Ltd. of U.K.
Aviation safety: Rapid test for harmful microbes in kerosene developed - Faster and more robust than a PCR test
Next generation solar fuels: How a record-breaking copper catalyst converts CO₂ into liquid fuels - Researchers have made real-time movies of copper nanoparticles as they evolve to convert carbon dioxide and water into renewable fuels and chemicals
Phenomenex: Zebron GC Columns Receive Two R&D 100 Awards
Rapid detection of antibiotic-resistant bacteria
